OverviewSuggest Edit

Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. The Company's molecules, whose systemic exposure is severely restricted, target transporters and receptors, modulating the uptake of nutrients or inducing secretion of key hormones to produce a therapeutic benefit in patients. Its non-systemic products act from within the intestines to avoid potential side effects that could occur with systemic exposure.
Ardelyx lead product, RDX5791, a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and for prevention of excess dietary sodium absorption, a new treatment modality for high blood pressure. RDX5791 is in phase 2 for IBS-C and a dose-ranging/regimen study for inhibition of excess dietary sodium absorption. Ardelyx is also developing RDX002, a minimally-absorbed, orally administered NaP2b phosphate transport inhibitor for the inhibition of phosphate absorption in patients with chronic kidney disease, and RDX009, a minimally-absorbed, orally administered TGR5 agonist for the treatment of type 2 diabetes through direct induction of intestinal incretins such as GLP-1 and PYY. 

TypePublic
Founded2007
HQFremont, CA, US
Websiteardelyx.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Dec 2019)88(+3%)
Job Openings18
Revenue (FY, 2020)$7.6 M(+44%)
Share Price (Jun 2021)$7.4(+3%)
Cybersecurity ratingBMore

Key People/Management at Ardelyx

Mike Raab

Mike Raab

President and Chief Executive Officer, Director
Robert Blanks

Robert Blanks

Chief Regulatory Affairs & Quality Assurance Officer
Jeff Jacobs

Jeff Jacobs

Chief Scientific Officer
Elizabeth Grammer

Elizabeth Grammer

Chief Legal & Administrative Officer
David Mott

David Mott

Chairman
Geoffrey A. Block

Geoffrey A. Block

Director
Show more

Ardelyx Office Locations

Ardelyx has offices in Fremont and Waltham
Fremont, CA, US (HQ)
34175 Ardenwood Blvd
Waltham, MA, US
200 West St 4th floor
Waltham, MA, US
400 5th Ave #210
Show all (3)

Ardelyx Financials and Metrics

Ardelyx Revenue

Ardelyx's revenue was reported to be $7.57 m in FY, 2020
USD

Revenue (Q1, 2021)

6.6m

Gross profit (Q1, 2021)

5.6m

Gross profit margin (Q1, 2021), %

84.8%

Net income (Q1, 2021)

(33.2m)

EBIT (Q1, 2021)

(32.0m)

Market capitalization (11-Jun-2021)

728.3m

Closing stock price (11-Jun-2021)

7.4

Cash (31-Mar-2021)

84.1m

EV

711.9m
Ardelyx's current market capitalization is $728.3 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

31.6m24.0m42.0m2.6m5.3m7.6m

Revenue growth, %

Cost of goods sold

8.4m466.0k600.0k145.0k

Gross profit

33.6m2.1m4.7m7.4m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

9.1m7.6m5.9m18.1m30.0k172.0k18.0k3.0m1.2m1.8m2.7m6.6m

Cost of goods sold

464.0k2.0k600.0k141.0k1.0m

Gross profit

170.0k2.4m1.7m5.6m

Gross profit Margin, %

99%80%92%85%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

107.3m107.0m74.6m75.4m78.8m181.1m91.0m

Accounts Receivable

2.6m2.6m10.8m85.0k

Prepaid Expenses

4.9m3.2m3.8m8.2m

Inventories

1.2m5.0m3.2m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(3.2m)(29.6m)(112.4m)(64.3m)(91.3m)(94.9m)(94.3m)

Depreciation and Amortization

302.0k829.0k1.3m2.6m2.7m2.5m1.8m

Inventories

(2.3m)

Accounts Payable

831.0k(371.0k)2.1m(1.0m)(2.7m)39.0k3.4m
USDQ2, 2014

Financial Leverage

2 x
Show all financial metrics

Ardelyx Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Ardelyx Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Ardelyx Online and Social Media Presence

Embed Graph

Ardelyx News and Updates

Ardelyx Announces Presentations at ERA-EDTA Virtual Congress 2021

FREMONT, Calif. and WALTHAM, June 7, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced two presentations...

Thinking about buying stock in Trevena, Windtree Therapeutics, Ardelyx, FreightCar America, or Soligenix?

NEW YORK, April 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRVN, WINT, ARDX, RAIL, and SNGX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...

Thinking about buying stock in Cara Therapeutics, Romeo Power, Ardelyx, LG Display, or Peabody Energy?

NEW YORK, April 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CARA, RMO, ARDX, LPL, and BTU. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Capricor Therapeutics, Cardtronics, Clearside Biomedical, Ardelyx, or FuelCell Energy?

NEW YORK, Jan. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, CATM, CLSD, ARDX, and FCEL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Ardelyx to Webcast Virtual Analyst Day

FREMONT, Calif., Nov. 6, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that it will hold a virtual Analyst Day on...

Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

FREMONT, Calif., March 6, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business highlights and financial results...
Show more

Ardelyx Blogs

Ardelyx to Present at the Jefferies 2021 Virtual Healthcare Conference

Ardelyx to Present at the Jefferies 2021 Virtual Healthcare Conference Content Import Tue, 05/25/2021 - 08:04 Ardelyx to Present at the Jefferies 2021 Virtual Healthcare Conference May 25, 2021 This release is a backfill from a News Wire Genera…

Ardelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights

Ardelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights Content Import Thu, 05/06/2021 - 08:05 Ardelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights May 6, 2021 This release is a backfill from a News W…

Ardelyx Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

FREMONT, Calif. and WALTHAM, Mass. , April 29, 2021 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases,

Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan

Ardelyx to Receive a $5 Million Milestone Payment FREMONT, Calif. and WALTHAM, Mass. , April 14, 2021 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal

Ardelyx Announces Upcoming Data Presentation at ISN World Congress of Nephrology 2021

FREMONT, Calif. and WALTHAM, Mass. , April 12, 2021 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that it will present a

Ardelyx Announces Poster Presentations, Educational Symposium, and Exhibitor Showcase at National Kidney Foundation 2021 Virtual Spring Clinical Meetings

FREMONT, Calif. and WALTHAM, Mass. , March 30, 2021 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that it will present two
Show more

Ardelyx Frequently Asked Questions

  • When was Ardelyx founded?

    Ardelyx was founded in 2007.

  • Who are Ardelyx key executives?

    Ardelyx's key executives are Mike Raab, Robert Blanks and Jeff Jacobs.

  • How many employees does Ardelyx have?

    Ardelyx has 88 employees.

  • What is Ardelyx revenue?

    Latest Ardelyx annual revenue is $7.6 m.

  • What is Ardelyx revenue per employee?

    Latest Ardelyx revenue per employee is $86 k.

  • Who are Ardelyx competitors?

    Competitors of Ardelyx include Sonnest, Asence Pharma and SciClone Pharmaceuticals.

  • Where is Ardelyx headquarters?

    Ardelyx headquarters is located at 34175 Ardenwood Blvd, Fremont.

  • Where are Ardelyx offices?

    Ardelyx has offices in Fremont and Waltham.

  • How many offices does Ardelyx have?

    Ardelyx has 3 offices.